ClinicalTrials.gg
CompletedNCT03837704Updated Aug 26, 2025Results posted

Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.

An interventional study of IQOS and Cigarette in Smoking, Abdominal Aortic Aneurysm and IQOS Use, sponsored by Philip Morris Products S.A.. Completed at 13 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2018, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Smoking by Philip Morris International — none open to participants now, 2 under way, none of them phase 3. Smoking · Philip Morris International.

Enrollment
24th of 32
48 · median 87
Started
2018
the only one that year
No phase
31 of 36
none open now
Registered
25th of 36
by date

Among the 36 studies in Smoking by Philip Morris International, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2018, is one of 31 with no phase, and was the 25th registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

None of the 36 studies in Smoking by Philip Morris International is open now. The open studies under Smoking, anywhere →

Who these studies take

Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Smoking by Philip Morris International as a file.
02

Study summary

The purpose of this study was to evaluate the reduction of the Abdominal Aortic Aneurysm (AAA) annual growth rate in patients who switched from smoking cigarettes to using IQOS as compared to patients who continued to smoke cigarettes, and to patients who had quit smoking. The study also aimed to provide context to the scale of reduction in the growth rate, by comparing the AAA annual growth rates for continuing to smoke and switching to IQOS with the AAA annual growth rate in smokers who had stopped smoking. The study further evaluated the effects of switching to IQOS on co-morbidities observed in AAA patients that are related to smoking as well as to assess the effects on relevant Biomarkers of Potential Harm (BoPH) linked to smoking related diseases.

Read the detailed description

This was a controlled, open-label, 3-arm parallel group, multi-center study in patients diagnosed with Abdominal Aortic Aneurysm (AAA) to evaluate the AAA annual growth rate in adult smokers randomized to either continue smoking combustible cigarettes (CC) or to switch to IQOS and in adults who had stopped smoking, as a non-randomized control arm.

This was a descriptive study, designed to gain an understanding of how changes in smoking behaviors impact AAA growth rate and disease progression. Therefore, there were no formal statistical hypotheses to be tested.

Smoking patients with AAA who did not quit smoking after their AAA diagnosis, and who were not intending to quit within the next 6 months were screened for enrollment and randomization in the CC and IQOS arms if all other eligibility criteria were met.

Smoking patients with AAA who had completely stopped smoking and using any other tobacco or nicotine-containing products within 2 months of their AAA diagnosis, and were still abstinent at the time of the Screening Visit and of the Baseline Visit were screened to be enrolled in the smoking cessation (SC) arm without randomization.

03

Conditions studied

  • Smoking
  • Abdominal Aortic Aneurysm
  • IQOS Use
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • Patient diagnosed with AAA (infrarenal, fusiform type) with a current aortic maximum minor-axis diameter of 30 to ≤ 49 mm (in male patient) and 30 to ≤ 44 mm (in female patient).
  • Patient has smoked on a daily basis (no brand restrictions) for at least 5 years prior to AAA diagnosis, based on self-reporting
  • Patient is ready to comply with the study protocol (e.g., to use their assigned product/regimen during the course of the study)

Inclusion criteria specific to patients screened for enrollment and randomization to the CC or IQOS arm:

  • Patient has smoked on average at least 5 commercially available CC per day (no brand restriction) for the last 12 months, based on self-reporting. Intermittent attempts to quit smoking not exceeding 2 months or short-term interruption of smoking up to 10 days within the last 12 months will be allowed. Smoking status will be verified based on a urinary cotinine test (i.e., cotinine ≥ 200 ng/mL).
  • Not intending to quit smoking within the next 6 months after having been advised to quit smoking.

Inclusion Criteria specific to patients screened for enrollment into the SC arm:

  • Patient had completely quit smoking and stopped the use of any other tobacco or nicotine-containing products within 6 months after AAA diagnosis, and is still abstinent at Screening and at Baseline. Smoking status will be verified based on a urinary cotinine test (i.e., cotinine \< 100 ng/mL).

Exclusion Criteria:

  • Patient is legally incompetent, physically or mentally incapable of giving consent.
  • Patient is a current or former employee of the tobacco industry or their first-degree relatives (parent and child); patient is an employee of the site or any other parties involved in the study or their first-degree relatives (parent and child).
  • Patient has been previously screened or enrolled in this study or was enrolled in any clinical study within 3 months prior to the Screening Visit.
  • Female patient who is pregnant or breast-feeding.
  • Patient is ineligible as judged by the Investigator to participate in the study for any reason.
  • Patient with acute severe cardiovascular events or respiratory diseases, within the last 3 months; with currently active cancer or history of cancer within the last 5 years; with dissecting aneurysm(s) of the aorta; with infrarenal pseudo-AAA (false AAA); with a diagnosis of Stage 3 and 4 in the medical history; with a recent (within 1 year) or current history of alcohol or other substance abuse based on self-reporting.
  • Patient with a diagnosis of concomitant genetic diseases such as but not limited to Marfan syndrome, Loeys-Dietz syndrome, Vascular Ehlers-Danlos syndrome, Turner syndrome, Polycystic kidney disease, Noonan syndrome, Alagile syndrome, Arterial tortuosity syndrome and Cutis laxa.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    IQOS Arm

    Patients diagnosed with AAA, switching from cigarette smoking to IQOS use

    Other: IQOS

  • Active comparator
    CC Arm

    Patients diagnosed with AAA, continuing to smoke cigarettes

    Other: Cigarette

  • Active comparator
    Smoking Cessation Arm

    Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)

    Other: Smoking Cessation

Interventions

  • OtherIQOS

    AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.

  • OtherCigarette

    AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.

  • OtherSmoking Cessation

    AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)

06

What researchers measure

Primary outcomes

  1. AAA Annual Growth Rate Over Time

    AAA annual growth rate will be measured in AAA patients who switch from smoking cigarettes to using IQOS, and AAA patients who continue to smoke CC, as compared to AAA patients who had stopped smoking. Maximum minor-axis AAA diameter in mm will be measured. Annual growth rate will be calculated by annualizing the slope of the linear regression over the available diameter measurements.

    Time frame: At 6-month intervals from baseline to V8 (month 36)

Secondary outcomes

  1. Percentage of Subjects Without Open Surgical AAA Treatment or AAA Endovascular Repair Over Time

    This outcome measured the percentage of subjects without surgery or endovascular repair over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.

    Time frame: From time of AAA diagnosis (prior to study participation) until V8 (month 36), a time frame of up to 7 years

  2. Percentage of Subjects Without Open Surgical AAA Treatment or AAA Rupture Over Time

    This outcome measured the percentage of subjects without surgery or AAA rupture over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.

    Time frame: From time of AAA diagnosis (prior to study participation) until V8 (month 36), a time frame of up to 7 years

  3. Incidence of Open Surgical AAA Treatment or AAA Endovascular Repair and AAA Rupture

    The incidence of open surgical AAA treatment or AAA endovascular repair and AAA rupture will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue to smoke CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually.

    Time frame: From baseline to V8 (month 36)

  4. Incidence of AAA Growth Above 5 mm Within 6 Months

    Incidence of AAA growth above 5 mm within 6 months will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually by counting the number of patients with an increase in maximum minor-axis AAA diameter of more than 5 mm within 6 months.

    Time frame: At 6-month intervals from baseline to V8 (month 36)

  5. AAA Patients With an Overall Maximum Minor-axis AAA Diameter of >55mm in Male Patients and >50mm in Female Patients

    The number of AAA patients with an overall maximum minor-axis AAA diameter \>55mm in male AAA patients and \>50mm in female AAA patients will be counted in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. (Note that the 95% CI is calculated by exact method (Clopper-Pearson) and refers to CI for a proportion).

    Time frame: From baseline to V8 (month 36)

  6. Systolic Blood Pressure

    This cardiovascular BoPH (systolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From V1 (screening) to V8 (month 36)

  7. Urinary Nicotine Equivalents (NEQ)

    To measure nicotine exposure over time in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC, and AAA patients who had stopped smoking. (NEQ adjusted for creatinine (mg/g creat)).

    Time frame: From baseline to V8 (month 36)

  8. Diastolic Blood Pressure

    This cardiovascular BoPH (diastolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From V1 (screening) to V8 (month 36)

  9. Body Weight

    This cardiovascular BoPH (body weight) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From V1 (screening) to V8 (month 36)

  10. Waist Circumference

    This cardiovascular BoPH (waist circumference) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From V1 (screening) to V8 (month 36)

  11. Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)

    This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From baseline to V8 (month 36)

  12. Total N-nitrosonornicotine (Total NNN)

    This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From baseline to V8 (month 36)

  13. 2-cyanoethylmercapturic Acid (2-CyEMA)

    This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

    Time frame: From baseline to V8 (month 36)

07

Results

Posted Aug 26, 2025
Limitations and caveats
This was an exploratory study not powered to detect a difference in AAA diameter between the different study arms. Due to patient recruitment challenges, only 48 patients out of the 114 planned were enrolled and the study was shortened from 5 to 3 years. Due to the limited sample size potential confounders could also not be adjusted for.

Participant flow

Completed V3 (Month 6)
Participant flow — Completed V3 (Month 6)
MilestoneIQOS ArmCC ArmSmoking Cessation Arm
Started161616
Completed161616
Not completed000
Completed V4 (Month 12)
Participant flow — Completed V4 (Month 12)
MilestoneIQOS ArmCC ArmSmoking Cessation Arm
Started161616
Completed161615
Not completed001
Completed V5 (Month 18)
Participant flow — Completed V5 (Month 18)
MilestoneIQOS ArmCC ArmSmoking Cessation Arm
Started161615
Completed161414
Not completed021
Completed V6 (Month 24)
Participant flow — Completed V6 (Month 24)
MilestoneIQOS ArmCC ArmSmoking Cessation Arm
Started161414
Completed141314
Not completed210
Completed V7 (Month 30)
Participant flow — Completed V7 (Month 30)
MilestoneIQOS ArmCC ArmSmoking Cessation Arm
Started141314
Completed141214
Not completed010
Completed V8 (Month 36)
Participant flow — Completed V8 (Month 36)
MilestoneIQOS ArmCC ArmSmoking Cessation Arm
Started141214
Completed131114
Not completed110

Outcome measures

PrimaryAAA Annual Growth Rate Over Time

AAA annual growth rate will be measured in AAA patients who switch from smoking cigarettes to using IQOS, and AAA patients who continue to smoke CC, as compared to AAA patients who had stopped smoking. Maximum minor-axis AAA diameter in mm will be measured. Annual growth rate will be calculated by annualizing the slope of the linear regression over the available diameter measurements.

Time frame:
At 6-month intervals from baseline to V8 (month 36)
Reported as:
Mean · (mm/year)
AAA Annual Growth Rate Over Time
(mm/year)IQOS ArmCC ArmSmoking Cessation Arm
AAA Annual Growth Rate Over Time1.80 (0.94 to 2.66)1.87 (1.33 to 2.40)1.27 (0.84 to 1.70)
SecondaryPercentage of Subjects Without Open Surgical AAA Treatment or AAA Endovascular Repair Over Time

This outcome measured the percentage of subjects without surgery or endovascular repair over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.

Time frame:
From time of AAA diagnosis (prior to study participation) until V8 (month 36), a time frame of up to 7 years
Reported as:
Number · percentage
Percentage of Subjects Without Open Surgical AAA Treatment or AAA Endovascular Repair Over Time
percentageIQOS ArmCC ArmSmoking Cessation Arm
Baseline -36 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Baseline -24 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)87.5 (58.6 to 96.7)
Baseline -12 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)87.5 (58.6 to 96.7)
V2 (Baseline)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)87.5 (58.6 to 96.7)
V4 (Month 12)83.9 (49.4 to 95.7)80.0 (40.9 to 94.6)87.5 (58.6 to 96.7)
V6 (Month 24)83.9 (49.4 to 95.7)80.0 (40.9 to 94.6)87.5 (58.6 to 96.7)
V8 (Month 36)83.9 (49.4 to 95.7)80.0 (40.9 to 94.6)87.5 (58.6 to 96.7)
SecondaryPercentage of Subjects Without Open Surgical AAA Treatment or AAA Rupture Over Time

This outcome measured the percentage of subjects without surgery or AAA rupture over time in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking.

Time frame:
From time of AAA diagnosis (prior to study participation) until V8 (month 36), a time frame of up to 7 years
Reported as:
Number · percentage
Percentage of Subjects Without Open Surgical AAA Treatment or AAA Rupture Over Time
percentageIQOS ArmCC ArmSmoking Cessation Arm
Baseline -36 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Baseline -24 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
Baseline -12 months100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
V2 (Baseline)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
V4 (Month 12)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
V6 (Month 24)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
V8 (Month 36)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)
SecondaryIncidence of Open Surgical AAA Treatment or AAA Endovascular Repair and AAA Rupture

The incidence of open surgical AAA treatment or AAA endovascular repair and AAA rupture will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue to smoke CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually.

Time frame:
From baseline to V8 (month 36)
Reported as:
Number · events per person-year
Incidence of Open Surgical AAA Treatment or AAA Endovascular Repair and AAA Rupture
events per person-yearIQOS ArmCC ArmSmoking Cessation Arm
Number of patients with open surgical AAA treatment or endovascular repair annually0.050.050.05
Number of patients with AAA rupture annually0.000.000.00
SecondaryIncidence of AAA Growth Above 5 mm Within 6 Months

Incidence of AAA growth above 5 mm within 6 months will be measured in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. Incidence rate will be calculated annually by counting the number of patients with an increase in maximum minor-axis AAA diameter of more than 5 mm within 6 months.

Time frame:
At 6-month intervals from baseline to V8 (month 36)
Reported as:
Number · events per person-year
Incidence of AAA Growth Above 5 mm Within 6 Months
events per person-yearIQOS ArmCC ArmSmoking Cessation Arm
Incidence of AAA Growth Above 5 mm Within 6 Months0 (0.0 to 0.2)0 (0.0 to 0.2)0 (0.0 to 0.2)
SecondaryAAA Patients With an Overall Maximum Minor-axis AAA Diameter of >55mm in Male Patients and >50mm in Female Patients

The number of AAA patients with an overall maximum minor-axis AAA diameter \>55mm in male AAA patients and \>50mm in female AAA patients will be counted in AAA patients who switch from smoking CC to using IQOS, as compared to AAA patients who continue smoking CC and AAA patients who had stopped smoking. (Note that the 95% CI is calculated by exact method (Clopper-Pearson) and refers to CI for a proportion).

Time frame:
From baseline to V8 (month 36)
Reported as:
Number · participants
AAA Patients With an Overall Maximum Minor-axis AAA Diameter of >55mm in Male Patients and >50mm in Female Patients
participantsIQOS ArmCC ArmSmoking Cessation Arm
AAA Patients With an Overall Maximum Minor-axis AAA Diameter of >55mm in Male Patients and >50mm in Female Patients0 (0.0 to 0.2)0 (0.0 to 0.2)0 (0.0 to 0.2)
SecondarySystolic Blood Pressure

This cardiovascular BoPH (systolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From V1 (screening) to V8 (month 36)
Reported as:
Mean · mmHg
Systolic Blood Pressure
mmHgIQOS ArmCC ArmSmoking Cessation Arm
V1 (Screening)134.8 (126.6 to 143.0)128.0 (119.1 to 136.9)124.0 (117.1 to 130.9)
V2 (Baseline)132.5 (122.9 to 142.1)128.9 (120.1 to 137.8)135.9 (129.7 to 142.2)
V3 (Month 6)138.8 (129.0 to 148.6)131.1 (123.8 to 138.5)130.3 (121.5 to 139.0)
V4 (Month 12)132.7 (125.5 to 140.0)135.0 (128.5 to 141.5)129.3 (121.2 to 137.5)
V5 (Month 18)133.9 (125.9 to 141.9)130.6 (124.6 to 136.7)126.9 (120.0 to 133.9)
V6 (Month 24)136.6 (127.3 to 146.0)129.7 (120.7 to 138.7)128.1 (121.1 to 135.2)
V7 (Month 30)128.8 (121.1 to 136.5)136.1 (130.5 to 141.7)126.0 (114.1 to 137.9)
V8 (Month 36)131.7 (124.6 to 138.8)131.6 (126.2 to 137.1)125.3 (116.5 to 134.0)
SecondaryUrinary Nicotine Equivalents (NEQ)

To measure nicotine exposure over time in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC, and AAA patients who had stopped smoking. (NEQ adjusted for creatinine (mg/g creat)).

Time frame:
From baseline to V8 (month 36)
Reported as:
Geometric mean · mg/g creat
Urinary Nicotine Equivalents (NEQ)
mg/g creatIQOS ArmCC ArmSmoking Cessation Arm
V2 (Baseline)5.70 (4.22 to 7.72)6.30 (4.16 to 9.54)0 (0 to 0)
V3 (Month 6)5.13 (4.06 to 6.47)7.46 (5.39 to 10.32)0 (0 to 0)
V4 (Month 12)4.30 (2.43 to 7.61)5.50 (3.16 to 9.59)0 (0 to 0)
V5 (Month 18)5.86 (3.18 to 10.78)0.0 (0.0 to 0.0)0 (0 to 0)
V6 (Month 24)4.65 (2.70 to 8.02)4.32 (1.97 to 9.48)0 (0 to 0)
V7 (Month 30)3.88 (2.22 to 6.78)4.24 (1.98 to 9.07)0 (0 to 0)
V8 (Month 36)0 (0 to 0)4.20 (1.46 to 12.07)0 (0 to 0)
SecondaryDiastolic Blood Pressure

This cardiovascular BoPH (diastolic blood pressure) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From V1 (screening) to V8 (month 36)
Reported as:
Mean · mmHg
Diastolic Blood Pressure
mmHgIQOS ArmCC ArmSmoking Cessation Arm
V1 (Screening)75.4 (69.6 to 81.1)76.6 (71.0 to 82.2)72.9 (67.5 to 78.4)
V2 (Baseline)76.6 (70.5 to 82.6)76.6 (71.5 to 81.6)77.3 (73.0 to 81.5)
V3 (Month 6)79.7 (75.0 to 84.3)77.3 (73.4 to 81.2)73.9 (68.1 to 79.6)
V4 (Month 12)76.3 (70.5 to 82.2)77.3 (70.8 to 83.7)74.1 (68.0 to 80.1)
V5 (Month 18)74.8 (69.2 to 80.4)78.3 (72.4 to 84.2)71.5 (67.4 to 75.6)
V6 (Month 24)79.0 (74.3 to 83.7)78.5 (71.6 to 85.5)72.7 (68.3 to 77.1)
V7 (Month 30)76.3 (72.5 to 80.1)79.8 (73.9 to 85.6)69.2 (62.9 to 75.5)
V8 (Month 36)73.8 (68.0 to 79.5)77.8 (70.7 to 84.9)67.0 (61.5 to 72.5)
SecondaryBody Weight

This cardiovascular BoPH (body weight) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From V1 (screening) to V8 (month 36)
Reported as:
Mean · kg
Body Weight
kgIQOS ArmCC ArmSmoking Cessation Arm
V1 (Screening)68.44 (61.68 to 75.19)66.63 (60.48 to 72.78)67.91 (62.34 to 73.48)
V2 (Baseline)68.13 (61.51 to 74.75)66.61 (60.47 to 72.74)67.93 (62.39 to 73.47)
V3 (Month 6)67.79 (61.04 to 74.54)65.88 (60.00 to 71.76)67.98 (62.56 to 73.40)
V4 (Month 12)68.47 (61.53 to 75.42)66.51 (60.42 to 72.59)67.27 (61.38 to 73.16)
V5 (Month 18)69.41 (62.02 to 76.81)67.60 (61.22 to 73.98)66.70 (60.47 to 72.93)
V6 (Month 24)68.51 (62.41 to 74.61)67.82 (60.19 to 75.45)67.14 (61.06 to 73.21)
V7 (Month 30)67.61 (61.70 to 73.53)69.08 (61.79 to 76.38)66.03 (59.84 to 72.22)
V8 (Month 36)68.74 (62.36 to 75.12)69.71 (61.56 to 77.86)66.34 (59.61 to 73.08)
SecondaryWaist Circumference

This cardiovascular BoPH (waist circumference) will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From V1 (screening) to V8 (month 36)
Reported as:
Mean · cm
Waist Circumference
cmIQOS ArmCC ArmSmoking Cessation Arm
V1 (Screening)90.51 (85.59 to 95.44)90.30 (85.11 to 95.49)91.40 (86.57 to 96.23)
V2 (Baseline)89.88 (84.61 to 95.14)91.01 (85.10 to 96.91)93.33 (88.80 to 97.85)
V3 (Month 6)89.95 (84.90 to 95.00)89.91 (84.06 to 95.75)91.16 (86.50 to 95.81)
V4 (Month 12)89.75 (84.17 to 95.34)89.46 (84.39 to 94.54)91.78 (86.74 to 96.82)
V5 (Month 18)91.73 (86.60 to 96.85)90.71 (84.99 to 96.42)91.82 (86.81 to 96.83)
V6 (Month 24)89.14 (81.91 to 96.36)91.55 (84.13 to 98.97)91.54 (86.91 to 96.16)
V7 (Month 30)89.04 (84.25 to 93.82)93.33 (86.51 to 100.16)91.43 (86.59 to 96.27)
V8 (Month 36)91.78 (87.65 to 95.90)92.30 (85.63 to 98.97)91.36 (85.93 to 96.79)
SecondaryTotal 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)

This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From baseline to V8 (month 36)
Reported as:
Geometric mean · pg/mg creat
Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)
pg/mg creatIQOS ArmCC ArmSmoking Cessation Arm
V2 (Baseline)124.09 (81.11 to 189.85)87.34 (55.98 to 136.27)0 (0 to 0)
V3 (Month 6)39.83 (17.74 to 89.41)108.70 (73.72 to 160.27)0 (0 to 0)
V4 (Month 12)27.12 (10.69 to 68.83)81.24 (52.33 to 126.12)0 (0 to 0)
V5 (Month 18)32.81 (12.77 to 84.33)61.85 (33.78 to 113.27)0 (0 to 0)
V6 (Month 24)33.02 (12.70 to 85.89)57.78 (31.17 to 107.11)0 (0 to 0)
V7 (Month 30)27.54 (10.09 to 75.21)61.78 (31.22 to 122.26)0 (0 to 0)
V8 (Month 36)35.24 (12.12 to 102.43)42.36 (15.30 to 117.29)0 (0 to 0)
SecondaryTotal N-nitrosonornicotine (Total NNN)

This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From baseline to V8 (month 36)
Reported as:
Geometric mean · pg/mg creatinine
Total N-nitrosonornicotine (Total NNN)
pg/mg creatinineIQOS ArmCC ArmSmoking Cessation Arm
V2 (Baseline)3.26 (1.78 to 5.97)2.09 (1.00 to 4.38)0 (0 to 0)
V3 (Month 6)1.39 (0.73 to 2.68)2.86 (1.61 to 5.09)0 (0 to 0)
V4 (Month 12)0.98 (0.42 to 2.30)2.12 (1.00 to 4.49)0 (0 to 0)
V5 (Month 18)1.28 (0.50 to 3.28)1.47 (0.54 to 4.00)0 (0 to 0)
V6 (Month 24)1.34 (0.51 to 3.52)1.55 (0.51 to 4.68)0 (0 to 0)
V7 (Month 30)1.20 (0.44 to 3.24)1.31 (0.50 to 3.48)0 (0 to 0)
V8 (Month 36)1.10 (0.37 to 3.27)1.27 (0.37 to 4.41)0 (0 to 0)
Secondary2-cyanoethylmercapturic Acid (2-CyEMA)

This biomarker of exposure to a tobacco smoke constituent will be measured in AAA patients who switch from smoking CC to using IQOS, AAA patients who continue to smoke CC and AAA patients who had stopped smoking.

Time frame:
From baseline to V8 (month 36)
Reported as:
Geometric mean · ng/mg creat
2-cyanoethylmercapturic Acid (2-CyEMA)
ng/mg creatIQOS ArmCC ArmSmoking Cessation Arm
V2 (Baseline)95.38 (71.93 to 126.48)98.95 (64.68 to 151.37)2.36 (1.36 to 4.10)
V3 (Month 6)20.21 (8.29 to 49.27)111.31 (74.30 to 166.76)1.67 (0.99 to 2.81)
V4 (Month 12)13.29 (4.61 to 38.34)82.46 (51.19 to 132.83)2.30 (1.10 to 4.80)
V5 (Month 18)12.53 (4.58 to 34.27)56.77 (26.94 to 119.63)1.70 (0.82 to 3.51)
V6 (Month 24)13.88 (4.22 to 45.68)48.40 (18.83 to 124.44)1.77 (0.77 to 4.06)
V7 (Month 30)8.25 (2.72 to 24.99)52.08 (20.21 to 134.23)1.51 (0.76 to 3.01)
V8 (Month 36)12.32 (3.31 to 45.91)46.19 (13.07 to 163.23)1.86 (0.92 to 3.77)

Adverse events

Collected over Adverse events were collected from the signature of the ICF by each subject until the end of the safety follow-up period, a total duration for each subject of up to 37 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IQOS Arm1/16 (6.3%)3/16 (18.8%)14/16 (87.5%)
CC Arm1/16 (6.3%)5/16 (31.3%)13/16 (81.3%)
Smoking Cessation Arm0/16 (0%)7/16 (43.8%)14/16 (87.5%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventIQOS ArmCC ArmSmoking Cessation Arm
Large intestine polypGastrointestinal disorders0/161/163/16
Atrial fibrillationCardiac disorders2/160/160/16
DeathGeneral disorders1/160/160/16
Angina unstableCardiac disorders0/161/160/16
Acute myocardial infarctionCardiac disorders0/160/161/16
Angina pectorisCardiac disorders0/160/161/16
Cardiac failureCardiac disorders0/160/161/16
Myocardial ischaemiaCardiac disorders0/160/161/16
CataractEye disorders0/161/160/16
IleusGastrointestinal disorders0/160/161/16
Most frequent other events
Showing 10 of 120
Most frequent other events
EventIQOS ArmCC ArmSmoking Cessation Arm
Viral upper respiratory tract infectionInfections and infestations2/162/164/16
HypertensionsVascular disorders1/164/163/16
Herpes zosterInfections and infestations1/161/163/16
HyperuricaemiaMetabolism and nutrition disorders1/160/163/16
Vision blurredEye disorders2/160/160/16
ConstipationGastrointestinal disorders2/160/161/16
GastritisGastrointestinal disorders0/160/162/16
HaemorrhoidsGastrointestinal disorders0/160/162/16
Large intestine polypGastrointestinal disorders0/161/162/16
Oropharyngeal painGastrointestinal disorders0/160/162/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)IQOS ArmCC ArmSmoking Cessation ArmTotal
Mean71.0 ± 6.1970.4 ± 7.7371.3 ± 2.5970.9 ± 5.79
Sex: Female, Male
Sex: Female, Male(Participants)IQOS ArmCC ArmSmoking Cessation ArmTotal
Female0000
Male16161648
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IQOS ArmCC ArmSmoking Cessation ArmTotal
American Indian or Alaska Native0000
Asian16161648
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Nationality
Nationality(Participants)IQOS ArmCC ArmSmoking Cessation ArmTotal
Japanese16161648
Other0000
08

Study locations

13 sites
  • Chiba-Nishi General Hospital
    Matsudo, Chiba 270-2251, Japan
  • Tokyo Bay Urayasu Ichikawa Medical Center
    Urayasu, Chiba 279-0001, Japan
  • Fujita General Hospital
    Fujita, Fukushima 969-1793, Japan
  • Kitakanto Cardiology Hospital
    Shizukawa, Gunma 377-0061, Japan
  • Shonan Kamakura General Hospital
    Okamoto, Kamakura 247-8533, Japan
  • Atsugi City Hospital
    Atsugi, Kanagawa 243-8588, Japan
  • AOI Universal Hospital
    Kawasaki, Kanagawa 210-0822, Japan
  • Shin-Yurigaoka General Hospital
    Kawasaki, Kanagawa 215-0026, Japan
  • Saitama Cardiovascular and Respiratory Center
    Itai, Kumagaya 360-0197, Japan
  • Kishiwada Tokushukai Hospital
    Kishiwada, Osaka 596-8522, Japan
  • Kasukabe Chuo General Hospital
    Kasukabe, Saitama 344-0063, Japan
  • Okitama Public General Hospital
    Nanyō, Yamagata 992-0472, Japan
  • Omichikai Morinomiya Hospital
    Osaka, 536-0025, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Apr 2023, 54 months.

Results were first posted in Aug 2025, 2 years 4 months after primary completion.

Of 56 industry-sponsored interventional studies with no phase under Smoking, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 54 months is above that.

Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2019
First posted
Feb 12, 2019
StartActual
Oct 3, 2018
Primary completionActual
Apr 6, 2023
CompletionActual
Aug 28, 2023
Results first posted
Aug 26, 2025
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03837704
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Oct 3, 2018
Primary completion
Apr 6, 2023
Completion
Aug 28, 2023
Results posted
Aug 26, 2025
Last update
Aug 26, 2025

Study contacts

Xavier Jaumont, MD
study chair · Philip Morris Products SA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion